New study checks cancer Drug's impact on common medications
NCT ID NCT07486713
First seen Mar 24, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study looks at how the cancer drug olutasidenib changes the way the body processes other medications. Researchers will give a mix of test drugs to 16 adults with IDH1-mutated cancers (like AML or certain brain tumors) and measure their levels in the blood before and after olutasidenib treatment. The goal is to understand potential drug interactions, not to treat the cancer itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Presbyterian Hospital-Columbia University Medical Center
NOT_YET_RECRUITINGNew York, New York, 10032, United States
-
UCI Irvine Health
RECRUITINGOrange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.